Heteroscorpionate‐based heteroleptic copper(II) complexes: Antioxidant, molecular docking and in vitro cytotoxicity studies. (22nd May 2017)
- Record Type:
- Journal Article
- Title:
- Heteroscorpionate‐based heteroleptic copper(II) complexes: Antioxidant, molecular docking and in vitro cytotoxicity studies. (22nd May 2017)
- Main Title:
- Heteroscorpionate‐based heteroleptic copper(II) complexes: Antioxidant, molecular docking and in vitro cytotoxicity studies
- Authors:
- Jayakumar, S.
Mahendiran, D.
Viswanathan, V.
Velmurugan, D.
Kalilur Rahiman, A. - Abstract:
- Abstract : Three new heteroscorpionate ligands, (2‐hydroxyphenyl)bis(imidazol‐1‐yl)methane (HL 1 ), (4‐diethylamino‐2‐hydroxyphenyl)bis(imidazol‐1‐yl)methane (HL 2 ) and (5‐bromo‐2‐hydroxyphenyl)bis(imidazol‐1‐yl)methane (HL 3 ), and their heteroleptic copper(II) complexes of the type [Cu(L 1–3 )diimine]ClO4 (1 –6 ; where diimine =2, 2′‐bipyridyl or 1, 10‐phenanthroline) have been synthesized and characterized using spectroscopic methods. The molecular structure of ligand HL 1 was determined by single‐crystal X‐ray diffraction. UV–visible, electron paramagnetic resonance and theoretical studies suggest a distorted square pyramidal geometry around copper(II) ion. Analyses of highest occupied and lowest unoccupied molecular orbitals have been used to explain the charge transfer taking place within the complexes. The antioxidant activities of the heteroscorpionate ligands and their heteroleptic copper(II) complexes were determined using ABTS, DPPH and H2 O2 free radical scavenging assays with respect to standard antioxidant ascorbic acid. In molecular docking studies, the complexes showed π–π, hydrogen bonding, van der Waals and electrostatic interactions with fibroblast growth factor receptor kinase. In vitro cytotoxicity activities of ligands and copper(II) complexes were examined on human breast adenocarcinoma (MCF‐7), cervical (HeLa) and lung (A549) cancer cell lines and normal human dermal fibroblast cell line using MTT assay. Complex 4 exhibited higher anticancer activityAbstract : Three new heteroscorpionate ligands, (2‐hydroxyphenyl)bis(imidazol‐1‐yl)methane (HL 1 ), (4‐diethylamino‐2‐hydroxyphenyl)bis(imidazol‐1‐yl)methane (HL 2 ) and (5‐bromo‐2‐hydroxyphenyl)bis(imidazol‐1‐yl)methane (HL 3 ), and their heteroleptic copper(II) complexes of the type [Cu(L 1–3 )diimine]ClO4 (1 –6 ; where diimine =2, 2′‐bipyridyl or 1, 10‐phenanthroline) have been synthesized and characterized using spectroscopic methods. The molecular structure of ligand HL 1 was determined by single‐crystal X‐ray diffraction. UV–visible, electron paramagnetic resonance and theoretical studies suggest a distorted square pyramidal geometry around copper(II) ion. Analyses of highest occupied and lowest unoccupied molecular orbitals have been used to explain the charge transfer taking place within the complexes. The antioxidant activities of the heteroscorpionate ligands and their heteroleptic copper(II) complexes were determined using ABTS, DPPH and H2 O2 free radical scavenging assays with respect to standard antioxidant ascorbic acid. In molecular docking studies, the complexes showed π–π, hydrogen bonding, van der Waals and electrostatic interactions with fibroblast growth factor receptor kinase. In vitro cytotoxicity activities of ligands and copper(II) complexes were examined on human breast adenocarcinoma (MCF‐7), cervical (HeLa) and lung (A549) cancer cell lines and normal human dermal fibroblast cell line using MTT assay. Complex 4 exhibited higher anticancer activity than the other complexes against all three cancer lines, being more potent than the standard drug cisplatin. Abstract : Six heteroscorpionate‐based heteroleptic copper(II) complexes have been synthesized and characterized. The antioxidant activity was performed using three different methods. In vitro cytotoxicity was performed against three cancerous and one normal cell lines by MTT assay. Molecular docking study was performed with FGFR kinase. The complex containing electron‐releasing substituent (─N(C2 H5 )2 ) and extended aromaticity exhibit highest biological activity. … (more)
- Is Part Of:
- Applied organometallic chemistry. Volume 31:Number 11(2017:Nov.)
- Journal:
- Applied organometallic chemistry
- Issue:
- Volume 31:Number 11(2017:Nov.)
- Issue Display:
- Volume 31, Issue 11 (2017)
- Year:
- 2017
- Volume:
- 31
- Issue:
- 11
- Issue Sort Value:
- 2017-0031-0011-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2017-05-22
- Subjects:
- antioxidant activity -- cytotoxicity -- heteroleptic complexes -- heteroscorpionate ligands -- molecular docking
Organometallic chemistry -- Periodicals
Organometallic compounds -- Periodicals
547.05 - Journal URLs:
- http://www3.interscience.wiley.com/cgi-bin/jhome/109566206 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/2676 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/aoc.3809 ↗
- Languages:
- English
- ISSNs:
- 0268-2605
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1576.270000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 18715.xml